Recognized as a PM360 Elite 100 Winner for 2026
Recognized for innovation in compliant social media management for regulated industries.
Reps post anyway from personal accounts, outside your systems. No visibility. No monitoring. No audit trail. They reference clinical data that was never MLR-approved for social — and you find out when compliance gets the call.
Well-meaning reps share trial data, efficacy claims, and patient anecdotes without MLR review. A patient comments with a side effect. Nobody escalates it. The FDA sees the post before your compliance team does.
Reps share only MLR-reviewed content from a curated portal — in one click. Comments are monitored for adverse events. Every share is logged. Reach grows. Risk doesn't.
AE Monitoring on All Advocacy Posts
The Problem
"We told reps not to post. Three months later, we found 40 unsanctioned LinkedIn posts about our pipeline drug — from our own sales team."
— VP Regulatory Affairs, Top-10 Pharma
Sales reps and MSLs are on the front lines of HCP relationships — and they know it. LinkedIn is where they build credibility, share scientific content, and stay visible between in-person calls. Telling them to stay off social is increasingly unrealistic.
The result is a compliance gap hiding in plain sight: employees posting about your drugs, your data, and your patients — outside of every MLR, monitoring, and audit system your company has built.
Your compliance team has no system to see, track, or log what reps are saying about your products across hundreds of personal LinkedIn accounts. The first sign of trouble is usually a regulator's inquiry.
Reps share efficacy data from congress slides, internal presentations, or memory — none of it reviewed for social promotion under 21 CFR Part 202. Even accurate data becomes a violation when shared in the wrong context.
Patients follow reps. They comment on personal posts with side effects, drug interactions, and disease progression. These comments are reportable AEs — but without monitoring, they're invisible to your Pharmacovigilance team.
The FDA holds the company — not the individual employee — accountable for promotional content. "We didn't know about it" has never been an acceptable response to an OPDP inquiry.
When inspectors ask for records of social media activity related to your product, you have marketing's posts — and nothing else. Reconstructing 18 months of rep activity manually is neither feasible nor sufficient.
Your EU reps share the same content as US reps — but EMA rules differ from FDA rules. A post compliant in one market may constitute unauthorized promotion in another.
